Market Closed -
Nasdaq
04:30:01 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
2
USD
|
0.00%
|
|
+11.11%
|
-50.70%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
-
|
-
|
76.24
|
132.7
|
6.858
|
2.14
|
Enterprise Value (EV)
1 |
-
|
-
|
77.91
|
126.4
|
1.228
|
1.218
|
P/E ratio
|
-
|
-
|
-4.13
x
|
-6.02
x
|
-0.17
x
|
-0.08
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-14.1
x
|
-8.14
x
|
-0.07
x
|
-0.09
x
|
EV / FCF
|
-
|
-
|
10,001,386
x
|
-21,737,542
x
|
-59,737
x
|
-200,075
x
|
FCF Yield
|
-
|
-
|
0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
-5.31
x
|
8.66
x
|
2.36
x
|
3.38
x
|
1.12
x
|
-17
x
|
Nbr of stocks (in thousands)
|
-
|
-
|
73.5
|
89.5
|
106
|
528
|
Reference price
2 |
3,876
|
4,064
|
1,037
|
1,482
|
64.41
|
4.056
|
Announcement Date
|
2/10/20
|
10/9/20
|
7/9/21
|
3/31/22
|
3/31/23
|
3/25/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-8.721
|
-20.79
|
-5.523
|
-15.53
|
-17.79
|
-13.37
|
EBIT
1 |
-8.744
|
-20.86
|
-5.648
|
-15.64
|
-17.9
|
-13.48
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-14.5
|
-25.4
|
-10.9
|
-20.35
|
-39.67
|
-22.28
|
Net income
1 |
-14.5
|
-25.39
|
-10.88
|
-20.32
|
-38.73
|
-19.94
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-251.3
|
-246.3
|
-387.2
|
-52.59
|
Free Cash Flow
|
-
|
-3.167
|
7.79
|
-5.815
|
-20.55
|
-6.089
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/10/20
|
10/9/20
|
7/9/21
|
3/31/22
|
3/31/23
|
3/25/24
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.217
|
-4.462
|
-3.681
|
-4.522
|
-4.055
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
18.29
|
1.03
|
1.564
|
2.939
|
-21.49
|
Net income
1 |
18.3
|
1.036
|
1.564
|
2.939
|
-21.49
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
87.40
|
19.00
|
19.00
|
34.20
|
-209.0
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
3/31/22
|
5/16/22
|
8/9/22
|
11/10/22
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
3.44
|
1.67
|
-
|
-
|
-
|
Net Cash position
1 |
0.57
|
-
|
-
|
6.27
|
5.63
|
0.92
|
Leverage (Debt/EBITDA)
|
-
|
-0.1657
x
|
-0.3029
x
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-3.17
|
7.79
|
-5.81
|
-20.6
|
-6.09
|
ROE (net income / shareholders' equity)
|
-
|
-164%
|
-31.6%
|
-58.4%
|
-153%
|
-355%
|
ROA (Net income/ Total Assets)
|
-
|
-48.9%
|
-6.57%
|
-16.5%
|
-27.2%
|
-67.6%
|
Assets
1 |
-
|
51.94
|
165.6
|
122.9
|
142.6
|
29.48
|
Book Value Per Share
2 |
-730.0
|
469.0
|
440.0
|
439.0
|
57.50
|
-0.2400
|
Cash Flow per Share
2 |
54.00
|
1.010
|
30.60
|
91.80
|
35.30
|
3.700
|
Capex
1 |
0.03
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/10/20
|
10/9/20
|
7/9/21
|
3/31/22
|
3/31/23
|
3/25/24
|
|
1st Jan change
|
Capi.
|
---|
| -50.70% | 1.71M | | -1.43% | 104B | | +8.96% | 105B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +6.79% | 14.16B | | +38.61% | 12.63B |
Bio Therapeutic Drugs
|